Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Jorge E Cortes

Showing results (11-20 of 417) with videos related to

Pageof 42
Sort By:
Therapeutic Advances in Hematology|February 27, 2023
Update on the role of gemtuzumab-ozogamicin in the treatment of acute myeloid leukemiaMahesh Swaminathan, Jorge E Cortes
Expert Opinion on Pharmacotherapy|December 7, 2014
New treatment for acute myelogenous leukemiaCourtney D DiNardo, Jorge E Cortes
Expert Opinion on Pharmacotherapy|March 15, 2025
Asciminib: the tyrosine kinase inhibitor with a unique mechanism of actionAkriti G Jain, Jorge E Cortes
Targeted Oncology|January 17, 2025
Bosutinib for the Treatment of CML-Using it Safely: a PodcastJeffrey H Lipton, Jorge E Cortes
Mayo Clinic Proceedings|July 14, 2006
Chronic myeloid leukemia: diagnosis and treatmentAlfonso Quintás-Cardama, Jorge E Cortes
Expert Opinion on Investigational Drugs|December 10, 2013
Tosedostat for the treatment of relapsed and refractory acute myeloid leukemiaCourtney D DiNardo, Jorge E Cortes
Hematology. American Society of Hematology. Education Program|December 4, 2016
Mutations in AML: prognostic and therapeutic implicationsCourtney D DiNardo, Jorge E Cortes
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|February 7, 2014
Omacetaxine: a protein translation inhibitor for treatment of chronic myelogenous leukemiaVarsha Gandhi, William Plunkett, Jorge E Cortes
Current Treatment Options in Oncology|March 14, 2017
Treatment of Relapsed/Refractory Acute Myeloid LeukemiaPrithviraj Bose, Pankit Vachhani, Jorge E Cortes
The New England Journal of Medicine|February 7, 2014
Ponatinib in Philadelphia chromosome-positive leukemiasJorge E Cortes, Moshe Talpaz, Hagop Kantarjian
Pageof 42

Showing results (11-20 of 417) with videos related to

Sort By:
Pageof 42
Therapeutic Advances in Hematology|February 27, 2023
Update on the role of gemtuzumab-ozogamicin in the treatment of acute myeloid leukemiaMahesh Swaminathan, Jorge E Cortes
Expert Opinion on Pharmacotherapy|December 7, 2014
New treatment for acute myelogenous leukemiaCourtney D DiNardo, Jorge E Cortes
Expert Opinion on Pharmacotherapy|March 15, 2025
Asciminib: the tyrosine kinase inhibitor with a unique mechanism of actionAkriti G Jain, Jorge E Cortes
Targeted Oncology|January 17, 2025
Bosutinib for the Treatment of CML-Using it Safely: a PodcastJeffrey H Lipton, Jorge E Cortes
Mayo Clinic Proceedings|July 14, 2006
Chronic myeloid leukemia: diagnosis and treatmentAlfonso Quintás-Cardama, Jorge E Cortes
Expert Opinion on Investigational Drugs|December 10, 2013
Tosedostat for the treatment of relapsed and refractory acute myeloid leukemiaCourtney D DiNardo, Jorge E Cortes
Hematology. American Society of Hematology. Education Program|December 4, 2016
Mutations in AML: prognostic and therapeutic implicationsCourtney D DiNardo, Jorge E Cortes
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|February 7, 2014
Omacetaxine: a protein translation inhibitor for treatment of chronic myelogenous leukemiaVarsha Gandhi, William Plunkett, Jorge E Cortes
Current Treatment Options in Oncology|March 14, 2017
Treatment of Relapsed/Refractory Acute Myeloid LeukemiaPrithviraj Bose, Pankit Vachhani, Jorge E Cortes
The New England Journal of Medicine|February 7, 2014
Ponatinib in Philadelphia chromosome-positive leukemiasJorge E Cortes, Moshe Talpaz, Hagop Kantarjian
Pageof 42